Red Flags Detected

  • Going Concern (worsened) — Going-concern disclosure now explicitly states insufficient cash for 12 months post-filing, versus 'more than one year' in baseline—a worsening liquidity outlook.
  • Material Weakness (improved) — Previously-disclosed material weakness in internal controls has been remediated through implementation of formal risk assessment and segregation of duties.
NASDAQ: TRAW Traws Pharma, Inc. 10-K

Traws reports going-concern warning, Symbio termination, and Phase 2 COVID data

Filed April 15, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TRAW commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.